Koenraad Blot
Profile
Koenraad Blot worked as an Executive Director of Clinical Research at Theratechnologies, Inc., Head of Medical Affairs and Clinical Operations at Pfizer Inc., and Chief Medical Officer at TiGenix NV and elbion NV.
He holds a doctorate from Ghent University and an undergraduate degree from the University of Antwerp.
Former positions of Koenraad Blot
| Companies | Position | End |
|---|---|---|
| TIGENIX NV | Chief Tech/Sci/R&D Officer | - |
| THERATECHNOLOGIES INC. | Chief Tech/Sci/R&D Officer | - |
| PFIZER, INC. | Chief Tech/Sci/R&D Officer | - |
elbion NV
 elbion NV Pharmaceuticals: MajorHealth Technology Elbion NV discovers and develops therapeutics for neurological diseases and immunological disorders. It focuses on the discovery and development of new drugs for CNS and immunological diseases. The company was founded by Dr. Thomas Kronbach and Dr. Bernd Kastler in 2002 and is headquartered in Leuven, Belgium. | Chief Tech/Sci/R&D Officer | - |
Training of Koenraad Blot
| Ghent University | Doctorate Degree |
| University of Antwerp | Undergraduate Degree |
Experiences
Positions held
Linked companies
| Listed companies | 2 |
|---|---|
| THERATECHNOLOGIES INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| Private companies | 2 |
|---|---|
elbion NV
elbion NV Pharmaceuticals: MajorHealth Technology Elbion NV discovers and develops therapeutics for neurological diseases and immunological disorders. It focuses on the discovery and development of new drugs for CNS and immunological diseases. The company was founded by Dr. Thomas Kronbach and Dr. Bernd Kastler in 2002 and is headquartered in Leuven, Belgium. | Health Technology |
TiGenix NV
 TiGenix NV Medical SpecialtiesHealth Technology TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products. The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells. It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction, and chronic cardiovascular indication. The company was founded by Gil Beyen and Frank P. Luyten on February 21, 2000 and is headquartered in Leuven, Belgium. | Health Technology |
- Stock Market
- Insiders
- Koenraad Blot
